|
|
| MRD / Regn No. |
: THBC\23-24\04549 |
Date |
: 20/07/2026 |
| Patient Name |
: Parmita Singh |
Age & Gender |
: 72 Yrs. / Female |
| Contact No. |
: 9920998829 |
UHID |
: |
| Ht / Wt / BMI |
: |
BP S / BP D |
: |
| Allergies |
: NONE |
Referred By |
: |
| |
|
| Problem
List |
: |
T2DM (04/Jul/2023) | HYPOTHYROIDISM (04/Jul/2017) | |
|
Subjective |
: |
T2DM SINCE 2023,HYPOTHYROIDISM SINCE 2017,F/H OF BOTH PARENTS - HTN,ARTHRITIS - GABAPIN,REC UTI - SS TO ALL ANTIBIOTICS |
|
Objective |
: |
19-JUL-2026 REPORTS,HB-9.5/ HBA1C-6.2%,FBS-124.06/ PPBS-184.38,TC-114/ TG-121/ LDL-71.9/ HDL-35,VITD-44/ VITB12-881,FT3-3.02/ FT4-1.39/ TSH-3.29,CR-0.71,NA-133.07/ K-4.74/ CL-99.98,ALT-26.6/ AST-33.4,HSCRP-2.15,EGFR-91,CORTISOL-11.5 |
|
Analysis |
: |
GABAPIN NT / OSTEOPHOS |
|
Plan |
: |
LONGER COURSE OF ANTIBIOTIC AS RECURRENCE - TO CHECK URINE R/M 2-3 DAYS AFTER STOPPING ANTIBIOTICS,AFTER REDCUING NIGHT DOSE - PLEASE CHECK FBS > 7 DAYS - IF STILL 30 MG BOTH TIMES |
|
|
|
S# |
Generic (Trade) Name |
Route |
Dosage |
Usage |
Duration |
|
1 |
TABLET METFORMIN 500MG
GLYCOMET 500 MG |
ORAL |
1-0-1 |
ABF / AD
|
4 MTHS |
|
|
2 |
THYRONORM 50 MCG |
ORAL |
1-0-0 |
BBF
|
4 MTHS |
|
|
3 |
STANLIP 145 / 160 MG |
ORAL |
0-0-1 |
AD
|
4 MTHS |
|
|
4 |
BIZFER XT |
ORAL |
0-1-0 |
BL / 3 DAYS A WEEK
|
4 MTHS |
|
|
5 |
NEBICARD 5 MG |
ORAL |
1-0-0 |
ABF
|
4 MTHS |
|
|
6 |
MEPXL |
|
0-0-1 |
7 PM
|
3 MONTH |
| 7 PM | |
|
7 |
DIAMICRON XR 60 |
ORAL |
1-0-0 |
BEFORE BREAKFAST
|
4MTHS |
|
|
8 |
DIAMICRON MR 30 MG |
ORAL |
0-0-1 |
BEFORE DINNER
|
4 MTHS |
|
|
9 |
TABLET CEFUROXIME AXETIL 500 MG
CEFTUM 500 MG |
PO |
1-0-1 |
ABF / AD
|
14 DAYS |
|
|
10 |
MAXEBOLT |
|
1/2-0-1/2 |
|
10 DAYS |
|
|
| |
|
|
|
| Refill :
0 / Substitution: |
|
|
| Education |
: IF LOW SUGARS (<70 MG/DL),TAKE 1 TBSP(15GMS) GLUCOSE POWDER. CHECK AGAIN AFTER 15 MINS IF >100 CAN GIVE A PROTEIN MEAL. |
| Next Visit |
: 02/Aug/2026 |
| Tests Suggested For Next Visit |
: USG ABDOMEN ESP KUB / PELVIS TO R/O CALCULUS OR BLADDER ABNORMALITY,AFTER 4 MTHS - HBA1C / TSH / FBS / PPBS |
| |
|
| |
|
|
